Vontobel Holding Ltd. Purchases New Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Vontobel Holding Ltd. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,817 shares of the medical research company's stock, valued at approximately $335,000.

Other institutional investors have also modified their holdings of the company. Asset Management One Co. Ltd. grew its stake in shares of Charles River Laboratories International by 1.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 18,918 shares of the medical research company's stock worth $3,522,000 after purchasing an additional 315 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. North Growth Management Ltd. grew its stake in shares of Charles River Laboratories International by 18.2% during the fourth quarter. North Growth Management Ltd. now owns 39,000 shares of the medical research company's stock worth $7,168,000 after purchasing an additional 6,000 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Charles River Laboratories International by 2.3% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,951 shares of the medical research company's stock worth $1,099,000 after purchasing an additional 133 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Charles River Laboratories International by 11.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 125,097 shares of the medical research company's stock worth $23,093,000 after purchasing an additional 13,102 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Birgit Girshick acquired 1,514 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

CRL has been the subject of several research analyst reports. StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and an average target price of $195.71.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded up $0.86 during midday trading on Friday, reaching $163.11. The company's stock had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average price of $173.39 and a 200 day moving average price of $188.81. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $275.00. The company has a market cap of $8.34 billion, a price-to-earnings ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the business earned $2.46 earnings per share. The firm's revenue was down 1.1% compared to the same quarter last year. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.41 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).